| Literature DB >> 33845460 |
Susan M Swetter1, John A Thompson2, Mark R Albertini3, Christopher A Barker4, Joel Baumgartner5, Genevieve Boland6, Bartosz Chmielowski7, Dominick DiMaio8, Alison Durham9, Ryan C Fields10, Martin D Fleming11, Anjela Galan12, Brian Gastman13, Kenneth Grossmann14, Samantha Guild15, Ashley Holder16, Douglas Johnson17, Richard W Joseph18, Giorgos Karakousis19, Kari Kendra20, Julie R Lange21, Ryan Lanning22, Kim Margolin23, Anthony J Olszanski24, Patrick A Ott25, Merrick I Ross26, April K Salama27, Rohit Sharma28, Joseph Skitzki29, Jeffrey Sosman30, Evan Wuthrick31, Nicole R McMillian32, Anita M Engh32.
Abstract
Over the past few years, the NCCN Guidelines for Melanoma: Cutaneous have been expanded to include pathways for treatment of microscopic satellitosis (added in v2.2020), and the following Principles sections: Molecular Testing (added in v2.2019), Systemic Therapy Considerations (added in v2.2020), and Brain Metastases Management (added in v3.2020). The v1.2021 update included additional modifications of these sections and notable revisions to Principles of: Pathology, Surgical Margins for Wide Excision of Primary Melanoma, Sentinel Lymph Node Biopsy, Completion/Therapeutic Lymph Node Dissection, and Radiation Therapy. These NCCN Guidelines Insights discuss the important changes to pathology and surgery recommendations, as well as additions to systemic therapy options for patients with advanced disease.Entities:
Year: 2021 PMID： 33845460 DOI： 10.6004/jnccn.2021.0018
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908